Last reviewed · How we verify
Flexyn2a
Flexyn2a is a monoclonal antibody that targets the PD-1 receptor.
Flexyn2a is a monoclonal antibody that targets the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | Flexyn2a |
|---|---|
| Sponsor | LimmaTech Biologics AG |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By binding to PD-1, Flexyn2a prevents the interaction between PD-1 and its ligands, leading to the activation of T cells and enhanced anti-tumor immune response.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pruritus
Key clinical trials
- Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a (PHASE2)
- Safety and Tolerability of a Bioconjugate Vaccine Against Shigella Flexneri 2a (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Flexyn2a CI brief — competitive landscape report
- Flexyn2a updates RSS · CI watch RSS
- LimmaTech Biologics AG portfolio CI